Skip to main content

CalAmp Corp Value Stock - Dividend - Research Selection

Calamp

ISIN: US1281261099 , WKN: A0B7RX

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

CalAmp Corp. provides Internet of Things (IoT) enablement solutions for various mobile and fixed applications worldwide. The company provides solutions for mobile resource management and applications for the IoT market, which enable customers in the transportation, government, construction, automotive, and energy markets to optimize their operations by collecting, monitoring, and reporting business-critical data and desired intelligence from remote and mobile assets. It also offers a portfolio of wireless communications products, such as asset tracking devices, mobile telemetry units, fixed and mobile wireless gateways, and multi-mode wireless routers; and cloud-based telematics software-as-a-service and platform-as-a-service applications. The company sells its products and services through direct and indirect sales channels in the United States, as well as through sales personnel in Latin America, the Middle East, and Europe. CalAmp Corp. was founded in 1981 and is headquartered in Irvine, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Camp4 Therapeutics Seeks to Raise Up to $100 Million in Private Placement; Shares Up Pre-Bell

2025-09-10
Camp4 Therapeutics (CAMP) said Wednesday that it has signed agreements with certain investors to rai

CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders

2025-09-10
Oversubscribed Financing led by Coastlands Capital with participation from new and existing investors Financing to provide $50 million in upfront proceeds with the potential for up to an additional $50 million of proceeds to fund the Phase 1/2 clinical trial in patients with SYNGAP1-related disorders, expected to initiate as early as 2H 2026 Doug Williams, Ph.D., to become Board Chair, and Dan Tardiff, Ph.D., elevated to Chief Scientific Officer CAMBRIDGE, Mass., Sept. 10, 2025 (GLOBE NEWSWIRE)

eGenesis Appoints Douglas Williams, Ph.D., and Adam Craig, M.D., Ph.D., to its Board of Directors

2025-08-19
CAMBRIDGE, Mass., August 19, 2025--eGenesis Appoints Douglas Williams, Ph.D., and Adam Craig, M.D., Ph.D., to its Board of Directors

CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights

2025-08-14
Presented positive translational data from SYNGAP1-related disorders program showcasing efficacy in a humanized SYNGAP mouse model and increased protein in non-human primates at the 28th American Society of Gene and Cell Therapy (ASGCT) Annual MeetingInitiating GLP toxicology studies evaluating CMP-SYNGAP-01 in Q3 2025Dosing completed in multiple ascending dose (MAD) cohort 3 of CMP-CPS-001 and data from single ascending dose (SAD) & MAD cohorts expected in Q4 2025 CAMBRIDGE, Mass., Aug. 14, 202

Can Camp4 Therapeutics (NASDAQ:CAMP) Afford To Invest In Growth?

2025-06-28
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...